The median progression-free survival times for the pemetrexed/cisplatin and the gemcitabine/cisplatin arms were 6.4 and 5.5 months , respectively , in the TS-negative group and 5.9 and 5.3 months in the TS-positive group ( interaction P = .07 ) .